Eli Lilly’s tirzepatide shows promising results for obstructive sleep apnea in latest clinical trials
Eli Lilly and Company (NYSE: LLY) has announced promising results from the SURMOUNT-OSA phase 3 clinical trials of tirzepatide, a novel treatment aimed at moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Detailed results, published in The New England Journal of Medicine and presented at the American Diabetes Association’s 84th Scientific Sessions, reveal significant […]